Granules India facility gets 3 observations during USFDA audit

Published On 2015-12-22 06:27 GMT   |   Update On 2015-12-22 06:27 GMT

New Delhi: Drug firm Granules India has received three observations from the USFDA for its Jeedimetla, Hyderabad facility during a recent inspection.



US Food and Drug Administration (USFDA) completed the inspection of company's two facilities, one located at Vizag in Andhra Pradesh and another at Jeedimetla in Telangana, Granules India said in a regulatory filing.

"There are no observations for Vizag facility and three observations for Jeedimetla facility. The company will respond to the observations in 15 business days", it added.

The Hyderabad-based firm serves customers in over 60 countries and has manufacturing footprint in India and China.

It has three facilities in Hyderabad and one in Jingmen, China. A fifth factory is under construction in Vizag through its JV company Granules OmniChem.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News